Background It has been reported that both nicorandil and magnesium have a cardioprotective effect in experimental ischemia -reperfusion models. In the present study, the cardioprotective effects of nicorandil and magnesium as an adjunct to reperfusion therapy in patients with acute myocardial infarction (AMI) were compared.
eperfusion therapy is effective in limiting the extent of infarction and preserving ventricular function in patients with acute myocardial infarction (AMI). 1,2 However, some patients do not experience these benefits even when early reperfusion is established, perhaps because of so-called reperfusion injury; 3 that is, restoration of blood flow to ischemic but reversibly injured cardiac cells may result in irreversible injury to those cells. This reperfusion injury constitutes a major hurdle in the current era of reperfusion therapy.
Nicorandil [N-(2-hydroxyethyl)-nicotinamide nitrate; Chugai Pharmaceutical Co Ltd, Tokyo, Japan] is a hybrid of an ATP-sensitive potassium channel (KATP) opener and a nitrate, and it is being used as anti-ischemic drug. 4 Magnesium is a physiologic calcium antagonist that inhibits the calcium influx to myocardial cells. 5 Previous experimental studies using ischemia -reperfusion models have demonstrated that both nicorandil and magnesium induce a striking enhancement of myocardial salvage and improvement of ventricular function. [6] [7] [8] [9] In some clinical studies, the administration of nicorandil with reperfusion therapy had a beneficial effect on the left ventricular function in AMI patients. [10] [11] [12] On the other hand, 2 large randomized clinical trials using magnesium for AMI gave conflicting results on mortality 13, 14 and it has been demonstrated that magnesium improved ventricular function in AMI patients who did not undergo reperfusion therapy. 15 However, there has not been a previous study that compared the cardioprotective effect of nicorandil and magnesium for AMI, which was the aim of the present study.
Methods

Study Patients
The present study included patients with AMI who were admitted to the Chiba Emergency Medical Center and underwent emergency coronary angiography (CAG) with stand-by PCI between June 1997 and September 1998. The diagnosis of AMI was made on the basis of chest pain lasting at least 30 min and ST-segment elevation electrocardiogram in 2 or more adjacent leads. Inclusion criteria were: (1) admission within 24 h of he onset of symptoms, (2) total or subtotal occlusion (Thrombolysis in Myocardial Infarction flow grade (TIMI) 0 or 1) 1 of the proximal or mid-left anterior descending coronary artery (LAD), (3) no prior myocardial infarction, (4) no or mild congestive heart failure (Killip I or II), (5) serum creatinine <2.0 mg/dl, and (6) age <80 years. In total, 40 consecutive patients were enrolled.
Study Protocol
The study protocol was approved by the Chiba Emergency Medical Center's Ethics Committee. Informed consent was obtained immediately after CAG. The patients were then randomized into 3 groups: (1) Group N (n=13): nicorandil was given at 4 mg intravenously (iv) and 4 mg intracoronarily (ic) before reperfusion, followed by continuous intravenous infusion at 4 mg/h for the subsequent 24 h, (2) Group M (n=13): magnesium sulfate given at 10 mmol iv before reperfusion, followed by continuous infusion at 0.4 mmol/h for the subsequent 24 h, and (3) Group C (n=14): neither magnesium nor nicorandil was given. Other vasodilators, inotropic agents and antiarrhythmic agents were administered if necessary.
Before catheterization, 10,000 IU of heparin was administered. CAG was performed with standard and orthogonal views, after which balloon angioplasty was performed in the standard manner. Coronary stents were placed when optimal angiographic results could not be obtained. Immediately after reperfusion was achieved, CAG and left ventriculography (LVG) were performed as baseline data.
The following data were collected at the time of reperfusion: (1) exacerbation of chest pain intensity, (2) ≥20 mmHg decrease of systolic blood pressure, (3) additional electrocardiographic ST-segment elevation in the V4 lead, and (4) reperfusion arrhythmia. The following arrhythmias that had not been observed before reperfusion and appeared immediately after reperfusion were considered as reperfusion arrhythmia: accelerated idioventricular or junctional rhythm, ventricular tachycardia (at least 3 beats) and ventricular fibrillation.
After cardiac catheterization, patients were maintained on 10,000-15,000 U/day of intravenous heparin for 24-48 h, and if necessary therapeutic doses of lidocaine, in the coronary care unit. They also received 81 mg/day of aspirin indefinitely. Calcium channel blockers, -adrenergic blocking agents, angiotensin-converting enzyme inhibitors and nitrates were given if necessary for the treatment of myocardial ischemia or hypertension.
Three months later, follow-up CAG and LVG were performed. Of the 40 patients, 4 had not undergone baseline LVG and 2 did not undergo follow-up LVG, so the comparison of baseline and follow-up LVG was performed in 34 patients.
Data Analysis
Quantitative CAG analysis was performed by experienced angiographers not involved in the imaging procedure, using the coronary end-diastolic frames from both acute and chronic CAG and a computer-assisted cineanalyzer (CCIP-310, Cathex, Tokyo, Japan). Successful reperfusion was defined as both diameter stenosis <50% and TIMI 3 flow on final baseline CAG and restenosis was defined as diameter stenosis >50% on follow-up CAG. To evaluate coronary blood flow after reperfusion, the TIMI frame count of LAD was calculated using the final baseline CAG. 16 All LVGs were analyzed with the same system as for CAG using the 30°right anterior oblique projection. The end-diastolic volume index (EDVI) and end-systolic volume index (ESVI) were measured by the area -length method on well-opacified LVG frames during normal sinus beats in the acute and chronic phases. The global ejection fraction (EF) was calculated as 100 × (EDV-ESV)/EDV. Regional wall motion (RWM) within the infarcted area was measured by the centerline method. 17 The area infarcted because of occlusion of the left anterior descending coronary artery was determined from chord numbers 10-66. 18 
Statistical Analysis
Results are expressed as mean ± SD or number (%). Statistical analysis among the 3 groups were performed by Analysis of Variance (ANOVA) or chi-square analysis followed by the Scheffe-type multiple comparison method. Serial changes in global and regional ventricular function were estimated by two-way repeated measure ANOVA. A probability value of <0.05 was considered significant.
Results
Patient Characteristics
The baseline characteristics were similar among the 3 groups ( Table 1 ). The mean reperfusion time was 363 min from onset of AMI, and 82.5% of the patients were reperfused within 8 h. All patients underwent PCI successfully, and coronary stents were placed in 25.0% of patients. The mean peak serum creatine kinase was 6,635±2,742 IU/L. There was no significant difference in the use of cardioprotective agents such as -adrenergic blocking agents or angiotensin-converting enzyme inhibitors.
Exacerbation of chest pain intensity, additional ST-segment elevation and reperfusion arrhythmia were observed with less frequency in the 2 treated groups than in Group C; however there was no significant difference ( Table 2 ). All patients were discharged alive, but 1 patient in Group C died because of congestive heart failure after discharge.
CAG and LVG
There were no significant differences in restenosis rates ( Table 1 ). The TIMI frame count of LAD on the baseline CAG was similar among the 3 groups (Group N: 26.8±9.9, Group M: 25.3±8.5, Group C: 28.9±12.7; NS).
Among the 3 groups, there was no significant difference in EDVI, ESVI or EF on both baseline and follow-up. In Groups C and M, a substantial increase in the EDVI from baseline to follow-up was observed. In contrast, there was no significant change in the EDVI of Group N. A considerable increase in the ESVI from baseline to follow-up was also observed in Group C, whereas there was no significant change in the ESVI of Groups N and M. A substantial improvement in EF was not observed in any of the groups. There was no significant difference in RWM among the 3 Change in regional wall motion (RWM) (follow-up RWMbaseline RWM). Group N showed greater improvement than Group C, with significant difference. In contrast, there was no significant difference between Groups M and C.
groups; however, a significant improvement of RWM from baseline to follow-up was demonstrated in Group N, but not in Groups M and C (Table 3 ). The change in RWM (follow-up RWM -baseline RWM) in Group N was significantly greater than that in Group C, but not in Group M (Fig 1) . There was no significant difference in the change of RWM between Groups M and C.
Discussion
The present study is the first randomized clinical trial to compare nicorandil and magnesium as adjunct cardioprotective agents to PCI in antero-septal AMI. In spite of its design for multiple comparisons and the small study population, the results demonstrate that early administration of nicorandil as an adjunct to PCI improves the RWM of the infarcted area and prevents enlargement of the left ventricle in patients with AMI without any adverse effects and to a greater extent than either magnesium or no treatment.
Previous Studies of Reperfusion Injury
There is a large body of experimental evidence indicating that reperfusion has deleterious effects on viable myocardium, the so-called reperfusion injury. The precise pathogenesis is still unclear, but various possibilities, including calcium overload, oxygen free radicals, neutrophils, cytokines and microcirculatory disturbances, have been considered. 19, 20 Although various pharmacological agents have been reported to reduce infarct size in ischemia -reperfusion models, many of them, such as diltiazem, 21 Na + /H + exchange inhibitor 22 and anti-CD11/CD18 monoclonal antibody, 23 have failed to show a clinical cardioprotective effect in reperfused AMI patients. On the other hand, platelet glycoprotein IIb/IIIa receptor blocker has shown significant benefit in the recovery of microvascular perfusion and ventricular contractile function as an adjunct to coronary stent implantation in AMI. 24 The Acute Myocardial Infarction Study of ADenosine (AMISTAD) trial revealed that administration of intravenous adenosine before reperfusion therapy reduced infarct size in patients with acute anterior infarction. 25 
Previous Studies of Nicorandil and Magnesium Therapy for AMI
There is growing evidence that nicorandil is a useful therapy for patients with AMI. Some studies have indicated that the administration of nicorandil as an adjunct to reperfusion therapy results in additional improvement of ventricular function and clinical outcomes in AMI. Ito et al demonstrated that the intravenous administration of nicorandil not only improved ventricular wall motion and prevented ventricular enlargement, but also reduced the frequency of congestive heart failure, malignant ventricular arrhythmia, cardiac tamponade and in-hospital death in patients with AMI undergoing primary angioplasty. 10 A recent report suggested that administration of nicorandil in the acute phase was associated with improved long-term clinical outcome of AMI patients. 26 Compared with nitroglycerin, administration of nicorandil enhanced recovery of left ventricular RWM during PCI. 27 However, there has not been a prior comparison of nicorandil and other cardioprotective agents in patients with AMI.
Magnesium, which regulates various processes in cellular metabolism, is considered to be beneficial for AMI patients. Several experimental studies 8, 9 have suggested that magnesium limits reperfusion injury when administered early during infarction and controversial results from 2 large clinical trials support this hypothesis. 28 The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2), in which magnesium was administered prior to thrombolysis, demonstrated a 24% reduction in 28-day mortality in the magnesium group. 13 In contrast, the International Study of Infarct Survival (ISIS-4) in which magnesium was given after thrombolytic therapy, failed to show any beneficial effect. 14 In a more recent study, the administration of magnesium improved mortality and left ventricular function of patients with AMI who did not receive reperfusion therapy. 15 However, the cardioprotective effect of magnesium in patients who undergo primary PCI remains uncertain and there have not been any previous studies that compared the cardioprotective effect of nicorandil and magnesium in patients with AMI.
Comparison of the Cardioprotective Effects of Nicorandil and Magnesium
Both nicorandil and magnesium reduce infarct size in experimental ischemia -reperfusion models [6] [7] [8] [9] and some common mechanisms of both agents with regard to reperfusion injury have been reported. First, each agent inhibits calcium overload of the ischemic myocardium. Nicorandil opens the sarcolemmal KATP of the myocardium, shortens the action potential duration and in consequence, reduces calcium inflow into myocytes. 7 Magnesium prevents calcium overload as a physiological calcium antagonist. 29 Second, both these agents attenuate the production of free radicals created by activated neutrophils and which are considered to damage viable cardiomyocytes during reperfusion. 30, 31 Third, they are thought to possibly to inhibit platelet aggregation, which is considered to cause acute coronary syndrome and obstruct coronary flow. Moreover, vasodilatory and antiarrhythmic effects have been reported for both agents. 32, 33 Additionally, there are 2 more mechanisms that have been reported for nicorandil, but not for magnesium. First, recent experimental studies have suggested that mitochondrial KATP plays an important role in the cardioprotective effect of nicorandil against ischemic injury. 34 Opening of the mitochondrial KATP enhances ATP synthesis and stimulates mitochondrial respiration, both of which help to preserve intracellular ATP and produce direct myocardial protection during ischemia and reperfusion. 35 More recently, it has been demonstrated that a mitochondrial KATP opener attenuated chronic left ventricular remodeling in an ischemia -reperfusion model, 36 and nicorandil is also thought to be involved in the processing of ischemic preconditioning. It has been demonstrated that a lower concentration of nicorandil opens the mitochondrial KATP more than the sarcolemmal KATP and that the cardioprotective effect of nicorandil is prevented by 5-hydroxydecanoate, which blocks the mitochondrial KATP. 37 Second, some clinical investigators have argued that the cardioprotective effect of nicorandil in AMI patients results from restoration of the microcirculatory disturbance after reperfusion. Recent clinical investigations using myocardial contrast echocardiography have revealed the presence of the noreflow phenomenon, which reflects insufficient myocardial perfusion despite revascularization of the infarcted vessels. RWM after reperfusion, 11 and Ito et al ascertained that continuous intravenous infusion of nicorandil prior to reperfusion prevented the no-reflow phenomenon and preserved left ventricular function. 10 Because of these 2 important roles, it is considered that nicorandil is more effective than magnesium as a cardioprotective agent against reperfusion injury. Recently, the IONA study demonstrated that oral administration of nicorandil reduced the incidence of major coronary events and improved the long term outcome of patients with stable angina, 38 and it is expected that previous use of nicorandil will reduce the deleterious complications at the onset of AMI.
Study Limitations
The present study was designed for multiple comparisons and was carried out in a small study population. In expectation of the prevention of reperfusion injury during PCI, we decided that the initial dose of each drug would be higher than in previous studies. Despite intracoronary administration prior to reperfusion and the higher initial dose of nicorandil, the present study did not demonstrate additional cardioprotective effects more conclusively than previous studies. Because early administration of nicorandil improved RWM without preventing reperfusion phenomena such as exacerbation of chest pain intensity, additional ST-segment elevation and reperfusion arrhythmia, it is impossible to certify that the cardioprotective effect of nicorandil resulted from treatment of reperfusion injury. It is expected that early administration of nicorandil will improve the clinical outcome of AMI patients, but this study was too small to determine the long-term efficacy. Although magnesium failed to show any beneficial effects in the present study, it does not mean that the usefulness of magnesium for AMI is in any way criticized. The dose of magnesium administered after reperfusion therapy was lower than in either the LIMIT-2 or ISIS-4, study because we had previously experienced an extreme elevation of serum magnesium concentration when we administrated magnesium under the same protocol as those studies. Further randomized trials are needed to accurately evaluate the indication and appropriate dose of magnesium therapy for AMI as an adjunct to PCI.
We used the TIMI frame count to evaluate coronary flow and we failed to find improvement in coronary perfusion. Serial investigations of myocardial perfusion using contrast echocardiography, Doppler flow wire or radionuclear perfusion scanning may reveal the contribution of the 2 agents to microcirculatory integrity.
Conclusions
As an adjunct to PCI, nicorandil was useful for preserving the contractility of the infarcted myocardium and preventing an enlargement of the left ventricle in AMI without any adverse effects. On the other hand, magnesium failed to show a cardioprotective effect in this study. Early administration of nicorandil prior to reperfusion therapy in AMI may prevent reperfusion injury.
